Dianthus Therapeutics, Inc. /DE/ (DNTH) financials

Dianthus Therapeutics, Inc. /DE/ (DNTH) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Dianthus Therapeutics, Inc. /DE/ reported revenue of $2M, down 67.3% year over year, net income of -$162M and diluted EPS of -$4.20.

Revenue (fiscal 2025)

$2M

Revenue growth (fiscal 2025)

-67.3%

Net income (fiscal 2025)

-$162M

Diluted EPS (fiscal 2025)

-$4.20

Dianthus Therapeutics, Inc. /DE/ files with the U.S. Securities and Exchange Commission under CIK 0001690585, classified as Pharmaceutical Preparations.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.